News Quantified

PRQR – proqr therapeutics n.v. - ordinary shares (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

ProQR Therapeutics (NASDAQ: PRQR) had its price target raised by analysts at HC Wainwright from $10.00 to $12.00. They now have a "buy" rating on the stock.

ProQR Therapeutics (NASDAQ: PRQR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.

ProQR Announces Year End 2024 Operating and Financial Results

ProQR Therapeutics (NASDAQ: PRQR) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating. They now have a $4.00 price target on the stock.

ProQR Therapeutics (NASDAQ: PRQR) was upgraded by analysts at Citigroup Inc. from a "neutral" rating to a "buy" rating. They now have a $4.00 price target on the stock.

-0.8%

BEAT

11.1%

BEAT

Chardan Capital

Chardan Capital

Form EFFECT ProQR Therapeutics N.V.

Form 424B5 ProQR Therapeutics N.V.

Form S-8 ProQR Therapeutics N.V.

Form F-3 ProQR Therapeutics N.V.

Form 20-F ProQR Therapeutics N.V. For: Dec 31

Top News Gainers

3/13 ProQR Therapeutics NV (NASDAQ: PRQR) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 17.4%

10/16 ProQR prices stock offering; shares down 12% after hours [Seeking Alpha] 15.4%

7/12 ProQR Therapeutics NV (NASDAQ: PRQR) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 13.5%

11/20 ProQR Therapeutics NV (NASDAQ: PRQR) had its price target lowered by analysts at Citigroup Inc from $40.00 to $33.00. They now have a "buy" rating on the stock. 13.3%

11/1 ProQR Therapeutics NV (NASDAQ: PRQR) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 11.4%

2/6 ProQR Therapeutics Teams Up with the Foundation Fighting Blindness and Blueprint Genetics to Support the My Retina Tracker® Program for People Living with Inherited Retinal Diseases 10.5%

3/25 ProQR to Present Findings from Phase 1/2 Interim Analysis of QR-421a for Usher Syndrome 10.4%

10/10 ProQR Therapeutics NV (NASDAQ: PRQR) had its price target raised by analysts at Citigroup Inc from $34.00 to $40.00. They now have a "buy" rating on the stock. 8.0%

7/29 Form 6-K ProQR Therapeutics N.V. For: Jul 29 6.8%

5/24 ProQR Therapeutics NV (NASDAQ: PRQR) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 6.8%

Top News Decliners

3/31 Form 6-K ProQR Therapeutics N.V. For: Mar 31 -21.7%

3/14 ProQR Therapeutics NV (NASDAQ: PRQR) was downgraded by analysts at ValuEngine from a "strong-buy" rating to a "buy" rating. -10.6%

1/30 Form 6-K ProQR Therapeutics N.V. For: Jan 30 -10.3%

10/10 Form 6-K ProQR Therapeutics N.V. For: Oct 10 -9.7%

11/8 Form SC 13G ProQR Therapeutics N.V. Filed by: WELLINGTON MANAGEMENT GROUP LLP -9.3%

11/18 ProQR to Present at Upcoming Scientific Conferences -9.3%

8/14 ProQR Therapeutics NV (NASDAQ: PRQR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $10.00 price target on the stock. -8.1%

11/28 ProQR Therapeutics NV (NASDAQ: PRQR) was upgraded by analysts at ValuEngine from a "buy" rating to a "strong-buy" rating. -7.2%

2/26 Form 6-K ProQR Therapeutics N.V. For: Aug 31 -6.8%

9/30 ProQR to Present at Two Investor Conferences in October -6.6%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day